Member Info for liquid1

I've been waiting Months for this moment on #DDDD. The bulls will be in force above 103p. Fun begins once 135p blows. If positive news drop while the Monthly squeeze is breaking it will multi bag usually within a Day. The 4D beast is just awakening. Huge Targets! Strong Buy!!!

https://twitter.com/confluencetradr/status/1293830820751450112

The Company announces that it has changed its accounting reference date from 31st December to 28th February.



As a result of this change, the Company's next audited financial statements will be prepared in respect of the 14-month period to 28th April 2020 and are required to be published by no later than 28th August 2020.

https://www.investegate.co.uk/finablr-plc--fin-/rns/change-in-accounting-reference-date/202006231319458237Q/

The weakest link causing mayhem will be out by Early September, then and only then will the sp move north.

That will be good riddance of Richmond!

When are Phase 2 results due?

Foreign exchange firm Travelex has gone into administration with the loss of more than 1,300 UK jobs.

Administrators PwC said a cyber-attack earlier this year followed by the coronavirus crisis had "acutely" hit the firm.

Travelex was held to ransom by hackers in January after the cyber-attack forced it to turn off its systems.

PwC said that a so-called "pre-pack" administration deal had been reached which had saved 1,800 UK Travelex jobs.

https://www.google.co.uk/amp/s/www.bbc.co.uk/news/amp/business-53684484

Richmond causing all the grief in the share selling every effing day!

What a complete t*at! He could have accepted 20p offer! Greedy Barsteward only getting 8p for his sells!

Karma for being too greedy!

25 days to get the *anker out!

https://direct.euronext.com/AnnouncementRNSDetails.aspx?id=14644083

https://www.genengnews.com/covid-19-candidates/synairgen-sng001/

Candidate: SNG001

Type: Inhaled formulation of interferon beta-1a

Status: Synairgen said July 20 that SNG001 generated positive results in the Phase II SG016 trial (NCT04385095), which assessed the inhaled drug in hospitalized COVID-19 patients. The double-blind, placebo-controlled trial enrolled 220 patients (120 studied at home, 100 in hospitals).

The odds of developing severe COVID-19—requiring ventilation or resulting in death during the treatment period (Days 1–16) were shown to be reduced by 79% for patients receiving SNG001 compared to patients receiving placebo. During the treatment period, the company reported, patients who received SNG001 were also more than twice as likely to recover (defined as “no limitation of activities” or “no clinical or virological evidence of infection”) compared to placebo patients.

Breathlessness was markedly reduced in patients who received SNG001 compared to those receiving placebo, the company said, adding that three participants (6%) died after being randomized to placebo, compared with no deaths among SNG001 patients.

Must be a buy!

News please Art!

Date/Time Trade Price Vol. Value
03/08/2020 16:48 0.4004p 72,949,191 £292.10K

Date/Time Trade Price Vol. Value
03/08/2020 16:48 0.4004p 72,949,191 £292.10K

Subject to obtaining the necessary regulatory approvals, it is intended that Mr. Crawford's appointment will take effect from 1 August 2020.



Roger Lovering, Acting Chairman of Amigo, said:



"I am delighted that Glen has decided to re-join the company. He is a natural choice and brings experience and leadership to the company at this challenging time."



Mr. Crawford was appointed Chief Executive Officer of the Company in February 2016 and of Amigo Loans Ltd and Amigo Management Ltd in October 2015, but stepped down as Chief Executive Officer during April 2019 in order to undertake medical treatment. During his period as Chief Executive Officer of Amigo, Mr Crawford secured full FCA authorisation for the business and then led it through a period of significant growth, developed and optimised its funding structures, was responsible for the IPO of the business in July 2018 and for its first full year results as a public company for the year to March 2019.



Mr. Crawford commented:



"I am pleased to have this opportunity to step back into the driving seat at Amigo with the support of the board. I remain confident that with Amigo's excellent team pulling together, we can successfully navigate through the challenges facing the business and get back to focussing on meeting the day to day needs of our present and future customers, who are otherwise excluded from obtaining credit."

Wondergoals

You forget the government are a complete bunch of morons, and don't jump on great British inventions

Just take Novacyt which invented the 1st test in Feb., agot a CE mark and still the stupid current administration and its cronies state they did not have any tests!

Sub-Mariner in the filter box!

That's better

Correct Nation

"With the commercial terms settled"

Michelle*
@michelle_crypto
·
9m
#COPL the clock is ticking - on monster deal could see 1.5-2p

Essar deal to be finalised ANY DAY (04 Aug latest)

-All parties want this!! Essar will lose $63 mill if not signed

- Deal will mean funded drill! (up to 50 M)

- the field next door got acquired for $750 mil

"""""" but we both hope this will be wrapped up earlier than that""""""

Anytime by Tuesday if not before!

"With the commercial terms settled in the agreement in principal, the legal language over a number of agreements has largely been agreed upon. Both parties continue to work amicably towards completion and have agreed to extend the backstop date for two weeks, but we both hope this will be wrapped up earlier than that. We continue to look forward to the future working relationship with Essar to unlock the potential of OPL 226."

Hoping for 3rd time lucky for deal complition before 4th August

Did India just give the green light to Omega Diagnostics COVID-19 test kit?
July 25, 2020ShareBuyers Editorial Team
Add Comment
Omega Diagnostics rapid COVID-19 test kit may have received the seal of approval that it needs to begin being sold in India.

Earlier this month, it was reported that Omega Diagnostics COVID-19 test kit was on a list of kits approved for testing in India – but it still needed the actual approval before it begins sale of it, complete with relevant supporting technical data.

The approval had to come from the Central Drugs Standard Control Organisation (CDSCO) – the regulatory body for pharmaceuticals in India.

On Thursday CDSCO seemingly confirmed approval of the test in a public notice title “Rapid / CLIA / ELISA Kits approved for testing of Covid-19 as on 23.07.2020”

The highlighted Omega Diagnostics subsidiary on the list from CDSCO.
The above image highlights that subsidiary Omega Dx(Asia) Pvt Ltd. Omega Dx(Asia) now appears to have the required approval. Omega has previously noted that it already has an established sales team within India and is looking forward to trying to commercialise the test to a population of over 1.3 billion.

If this is indeed the confirmation needed – investors will be anticipating a RNS announcement announcement next week.

Conversations are believed to be in progress with the UK government about selling the COVID-19 test kits in the UK too as reported last week.

https://www.sharebuyers.co.uk/shares/did-india-just-give-the-green-light-to-omega-diagnostics-covid-19-test-kit/